List

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until April, 2020.

  1. Topic 375: 18F PET Tracer For Imaging PD-L1 (Moonshot)

    SBC: SIBTECH, INC.            Topic: NCI

    New therapies, designed to enhance anti-tumor immunity are based on the blockade of the checkpoint components, either PD-1 on immune cells or PD-L1 on tumor cells. This strategy, while being spectacularly successful in some patients for some cancers, fails for many other patients. The expression of PD-L1 is highly dynamic and its prevalence within tumors can vary significantly over time. The curre ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. HQ-55 VTOL UAS for Ship Based Operation

    SBC: Latitude Engineering, LLC            Topic: 832

    TECHNICAL ABSTRACT: The Hybrid Quadrotor concept, developed by Latitude Engineering, combines the high power density of electric motors and propellers with the high energy density of a piston engine and liquid fuel. Together, each technology enables maximum performance in HQ's two regimes of flight: the electric system is responsible for lift while hovering (high power, short endurance), and the g ...

    SBIR Phase II 2018 Department of CommerceNational Oceanic and Atmospheric Administration
  3. Randomized Prospective Phase II Clinical Trial of NVX in Association with Chemoradiation of Glioblastoma

    SBC: NUVOX PHARMA, L.L.C.            Topic: 102

    Glioblastoma multiforme GBM is a malignant primary brain tumor affecting about new cases per year in the U S Average survival is only about months Radiation RT is most commonly administered as fractions of Gray each over weeks with concomitant temozolomide TMZ GBM tumors are hypoxic The primary mechanism of RT is creation of singlet oxygen hypoxia within GBM adversel ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  4. A Rapid Low Cost Point of Care Diagnostic for detection of Zika virus RNA

    SBC: L2 DIAGNOSTICS, LLC            Topic: NIAID

    ABSTRACT Zika virus ZIKV has rapidly emerged and spread through South and Central America the Caribbean and Puerto Rico since its last outbreak in Micronesia in Transmitted by the mosquito Aedes sp its forecasted spread will have a major impact on the Southeast U S Most ZIKV infections remain asymptomatic or present with non specific rash and fever therefore they have been difficult ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Disaggregation of Toxic Protein Oligomers in Brain with Electromagnetic Treatment

    SBC: NeuroEM Therapeutics, Inc.            Topic: 104

    ABSTRACT Formation of misfolded protein oligomers in neurons is an early and causative event in a variety of neurodegenerative diseases such as Alzheimer s Disease amyloid and tau oligomers Fronto temporal lobe dementia tau oligomers and Parkinson s Disease synuclein oligomers These toxic oligomers share a common aggregation mechanism that involves formation of hydrogen bonds betwee ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Application of PPODA QT for embolization of aneurysms

    SBC: Aneuvas Technologies, Inc.            Topic: 101

    A cerebral aneurysm is an abnormal enlargement or pouch that forms from a weakened vessel segment in the brain Often going unnoticed and untreated an aneurysm can cause a sudden and catastrophic hemorrhage or stroke Approximately of patients die from an aneurysm rupture even before receiving medical attention and of patients die despite medical treatment Patients that survive typical ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Development of MTX for the Treatment of KRAS Mutant Colorectal Cancer

    SBC: Mekanistic Therapeutics, LLC            Topic: NCI

    PROJECT SUMMARY Mekanistic Therapeutics seeks to design discover and develop anti cancer agents that selectively inhibit multiple oncogenic pathways Its lead agent MTX was discovered in collaboration with the Leopold laboratory at University of Michigan MTX is a novel kinase inhibitor showing early promise for its therapeutic potential against solid cancers refractory to current treatm ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Commercial Software Using High throughput Computational Techniques to Improve Genome Analysis

    SBC: Genomenon, Inc.            Topic: 172

    Recent advances in DNA sequencing technology have not been matched by improved analytic techniques to quickly and accurately interpret patient genome data to inform diagnosis prognosis and therapy making decisions in the clinic and to identify candidate biomarkers of disease in research laboratories Development of automated techniques to facilitate interpretation of this data will benefit patien ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Regulators of NaV Channels Novel Anti Allodynic Drug Candidates

    SBC: Regulonix            Topic: 102

    PROJECT SUMMARY Chemotherapy induced peripheral neuropathy CIPN is a common prevalence and potentially dose limiting side effect of many cancer chemotherapy drug treatment regimens Clinically CIPN presents with pain that is burning shooting or electric shock like The increase in prevalence of cancer coupled with an increase in the cancer survival rates due to chemotherapy regimens ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. A nanoparticle delivery system for CRISPR Cas based therapeutics

    SBC: ATGC Inc.            Topic: NCATS

    Abstract Applications of customizable nucleases such as CRISPR clustered regularly interspaced short palindromic repeats Cas CRISPR associated protein have enabled efficient and precise gene correction in vitro and hold promises for eventually achieving in vivo gene correction therapy However to apply CRISPR Cas in therapeutic settings several major challenges remain to be addressed ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government